Moberg Pharma changes in Board of Directors
Posted: 17 November 2014 | | No comments yet
Moberg Pharma AB announces that George E. Aitken-Davies has resigned from the Board of Directors of Moberg Pharma in conjunction with the final earn-out payment related to the acquisition of Alterna LLC in 2012…
Moberg Pharma AB (OMX: MOB) announces that, effective as of today, George E. Aitken-Davies has resigned from the Board of Directors of Moberg Pharma in conjunction with the final earn-out payment related to the acquisition of Alterna LLC in 2012. Appointed by Altaris Capital Partners, George E. Aitken-Davies remains a member of the Nomination Committee of Moberg Pharma until the Annual General Meeting in May 2015.
“I would like to thank George for his valuable contributions to the board at Moberg Pharma. The acquisition in 2012 of Moberg Pharma North America (previously Alterna LLC), a former portfolio company of Altaris Capital Partners, has been a success and today represents two thirds of the sales of Moberg Pharma,” said Peter Wolpert, CEO of Moberg Pharma AB.
About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 pm (CET) on November 14, 2014.
